Background: The prevalence of neck pain among adults worldwide is 4.9-22.3%. It occurs in 34.7% of office workers in industrialized countries. Aim: To study the effect of massage therapy of Mongolian medicine on neck pain Materials and Methods: In this study, a parallel clinical trial design was used, and 50 patients with neck pain were divided into two groups: the treatment group received massage therapy of Mongolian medicine and the control group received exercise therapy, and the treatment results were compared. VAS assessment, NDI, Digital Algometer, and European Quality of Life Questionnaire were used in the study. Results: 52 % of the study participants were male, while 48 % were female, and their mean age was 43.3±21.3. The VAS score for pain assessment was 5.44±0.96 in the treatment group and 5.44±0.96 in the comparison group before treatment, but after the treatment it decreased to 0.80±0.71 in the treatment group and 1.44±0.77 in the comparison group, respectively, which showed a statistically significant difference. Massage therapy of Mongolian medicine has a greater pain-relieving effect than exercise therapy in the treatment of neck pain (p<0.01). The pressure pain threshold was 934±154.60 in the treatment group and 934±154.60 in the comparison group before treatment, but after treatment, it increased to 1536±22.91 in the treatment group and 1392±83.77 in the comparison group, which was statistically significant (p<0.01). The neck disability index of patients with neck pain was 11.44±2.87 in the treatment group and 11.56±2.55 in the comparison group before treatment, but after treatment it decreased to 0.84±0.69 in the treatment group and 1.40±0.87 in the comparison group. Although exercise therapy has the effect of reducing the neck disability index, when comparing the treatment results of the two groups, massage therapy of Mongolian medicine had greater effect (p<0.05). European Quality of Life Questionnaire was 8.64±2.25 in the treatment group and 8.16±1.60 in the comparison group before treatment, but after treatment it was 5.28±0.54 in the treatment group and 7.44±1.23 in the comparison group. Massage therapy of Mongolian medicine has a greater effect on improving the quality of life of people with neck pain compared to exercise therapy (p<0.01). The neck forward bending was 36.60±2.45 in the treatment group and 37.24±2.35 in the comparison group before treatment, but after treatment, it increased to 42.32±2.14 in the treatment group and 39.32±2.14 in the comparison group, which was statistically significant (p0.01).The neck abduction was 36.20±1.89 in the treatment group and 36.56±2.24 in the comparison group before treatment, but after treatment, it increased to 42.80±2.06 in the treatment group and 39.76±1.88 in the comparison group, which was statistically significant (p=0.01).The neck left rotation was 60.84±3.77 in the treatment group and 61.56±4.31 in the comparison group before treatment, but after treatment, it increased to 75.08±3.55 in the treatment group and 67.20±4.29 in the comparison group, which was statistically significant (p0.01). The neck right rotation was 61.80±4.39 in the treatment group and 62.00±4.42 in the comparison group before treatment, but after treatment, it increased to 76.52±2.95 in the treatment group and 68.04±4.46 in the comparison group, which was statistically significant (p0.01).When comparing the treatment results of the two groups, Mongolian medical bariatric surgery was more effective (p<0.01). Conclusions 1. Massage therapy of Mongolian medicine reduces disability index in people with neck pain (p<0.05). 2. Massage therapy of Mongolian medicine has a significant effect on reducing pain and pressure pain threshold in people with neck pain (p<0.01). 3. Massage therapy of Mongolian medicine has the effect of improving the quality of life of people with neck pain (p<0.01).

Humans ; Lung Transplantation/adverse effects* ; Risk Factors

Objective: To clarify the values of autotaxin (ATX) in patients with primary biliary cholangitis (PBC) and PBC-related hepatocellular carcinoma (HCC). Methods: 179 patients with PBC were selected from prospective cohorts of autoimmune liver diseases at the time of first diagnosis of PBC in Department of Hepatology, the Fifth Medical Center of PLA General Hospital, from January 2016 to January 2018, all patients with PBC received UDCA therapy, primary endpoint was event of HCC, the follow-up period was censored at the date of HCC. The relationship between level of ATX and clinical features in patients with PBC and its potential value in predicting disease progression and PBC-related HCC were analyzed. Results: The ATX level in the peripheral blood of patients with PBC was significantly higher than that of alcoholic liver cirrhosis(ALC) (t = 3.278, P = 0.001) and healthy controls(HC) (t = 6.594, P < 0.001), however, when comparing PBC to non-PBC related HCC, no significant difference was found between the groups(t=-0.240, P = 0.811). Consistent with peripheral blood levels, histochemical staining indicated that ATX in the liver of patients with PBC was significantly higher than that of HC (Z=-3.633, P < 0.001) and ALC (Z=-3.283, P < 0.001), and the expression of ATX in PBC with advanced histological stage was significantly higher than PBC with early stage (Z=-2.018, P = 0.034). The baseline ATX level in PBC patients without developing to HCC during follow-up had significant difference to patients with developing to HCC (228.451 ± 124.093 ng/ml vs 301.583 ± 100.512 ng/ml, t = 2.339, P = 0.021). The result in multivariate logistic regression analysis showed that ATX were independent predictors of PBC related HCC(OR 1.245, 95%CI 1.097-1.413). The optimal critical value of peripheral blood ATX level at baseline for predicting HCC was 235.254 ng/ml, with the cut-off value of 0.714 in AUC of the ROC (95% CI was 0.597~ 0.857), sensitivity and specificity were 84.6% and 59.0%, respectively. Conclusion: ATX level was significantly higher in PBC patients over controls, and it's concentration was correlated with UDCA efficacy and fibrosis stage. ATX has potential values in predicting disease progression and PBC-related HCC.

Humans ; Lung Neoplasms/pathology* ; Adenocarcinoma/pathology* ; Papilloma/genetics* ; Receptor, Fibroblast Growth Factor, Type 1/metabolism* ; Gene Amplification ; Carrier Proteins ; Cytoskeletal Proteins

Humans ; Thyroid Cancer, Papillary ; Neck/pathology* ; Lymph Nodes/pathology* ; Thyroid Neoplasms/pathology* ; Lymphoma, T-Cell/pathology*

Humans ; Carcinoma, Renal Cell/pathology* ; Kidney Neoplasms/pathology* ; Biomarkers, Tumor

Humans ; Lymphoma, B-Cell

Humans ; Colon, Descending ; Dendritic Cell Sarcoma, Follicular

Objective: To investigate the clinicopathological characteristics of plurihormonal PIT1-lineage pituitary neuroendocrine tumors. Methods: Forty-eight plurihormonal PIT1-lineage tumors were collected between January 2018 and April 2022 from the pathological database of Sanbo Brain Hospital, Capital Medical University. The related clinical and imaging data were retrieved. H&E, immunohistochemical and special stains were performed. Results: Out of the 48 plurihormonal PIT1-lineage tumors included, 13 cases were mature PIT1-lineage tumors and 35 cases were immature PIT1-lineage tumors. There were some obvious clinicopathological differences between the two groups. Clinically, the mature plurihormonal PIT1-lineage tumor mostly had endocrine symptoms due to increased hormone production, while a small number of immature PIT1-lineage tumors had endocrine symptoms accompanied by low-level increased serum pituitary hormone; patients with the immature PIT1-lineage tumors were younger than the mature PIT1-lineage tumors; the immature PIT1-lineage tumors were larger in size and more likely invasive in imaging. Histopathologically, the mature PIT1-lineage tumors were composed of large eosinophilic cells with high proportion of growth hormone expression, while the immature PIT1-lineage tumors consisted of chromophobe cells with a relatively higher expression of prolactin; the mature PIT1-lineage tumors had consistently diffuse cytoplasmic positive staining for keratin, while the immature PIT1-lineage tumors had various expression for keratin; the immature PIT1-lineage tumors showed more mitotic figures and higher Ki-67 proliferation index; in addition, 25.0% (12/48) of PIT1-positive plurihormonal tumors showed abnormal positive staining for gonadotropin hormones. There was no significant difference in the progression-free survival between the two groups (P=0.648) by Kaplan-Meier analysis. Conclusions: Plurihormonal PIT1-lineage tumor belongs to a rare type of PIT1-lineage pituitary neuroendocrine tumors, most of which are of immature lineage. Clinically increased symptoms owing to pituitary hormone secretion, histopathologically increased number of eosinophilic tumor cells with high proportion of growth hormone expression, diffusely cytoplasmic keratin staining and low proliferative activity can help differentiate the mature plurihormonal PIT1-lineage tumors from the immature PIT1-lineage tumors. The immature PIT1-lineage tumors have more complicated clinicopathological characteristics.
Humans ; Neuroendocrine Tumors ; Pituitary Neoplasms/pathology* ; Pituitary Hormones ; Growth Hormone/metabolism* ; Keratins

Animals ; Mice ; Colon ; Histological Techniques